Search Bar & Filters
Found 35 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating minimally invasive tests to diagnose pancreatic cancer early and monitor treatment response. This observational study focuses on pancreatic ductal adenocarcinoma and related pancreatic diseases, aiming to improve early detection and surveillance using blood-based biomarkers. The research is sponsored by Memorial Sloan Kettering Cancer Center and includes various patient groups with pancreatic cancer, benign pancreatic conditions, and healthy controls. Participants are divided into cohorts based on their diagnosis, including advanced pancreatic cancer, operable pancreatic cancer, acute and chronic benign pancreatic conditions, pancreatic cysts, and healthy individuals. Blood and sweat samples will be collected, and optional biopsies of tumor or cyst tissue may be performed. Sample collection occurs at enrollment and periodically every 6 to 12 months according to institutional guidelines, with some cohorts closed to new participants. During the study, participants will provide blood samples and possibly tissue samples if clinically safe. Researchers will analyze changes in biomarkers to assess the tests ability to detect early pancreatic cancer over four years. Monitoring includes collecting clinical information and samples at regular intervals. Participation involves ongoing assessments and sample collection to support biomarker development and validation.
Actively Recruiting
Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of apraglutide compared with a placebo in adults with short bowel syndrome associated with intestinal failure SBS-IF. This Phase 3, double-blind, randomized, placebo-controlled study aims to include about 124 adult participants who rely on parenteral support PS at least three days per week. Participants are stratified by anatomy and baseline PS volume to ensure balanced study groups. Participants will be randomly assigned to receive either weekly subcutaneous injections of apraglutide or placebo for 24 weeks. The study consists of four periods Screening including optimization and stabilization, Treatment, Safety Follow-up after the last dose, and an Anti-Drug Antibody Follow-up period. Those completing treatment may join a long-term extension study with apraglutide or complete a safety follow-up visit before entering the antibody monitoring phase. During the study, participants will have their weekly parenteral support volume measured to assess changes. Additional assessments include reductions in PS days per week, achievement of enteral autonomy, and patient-reported global impression of change. Safety will be monitored through adverse event tracking and laboratory tests. Participants are expected to adhere to fluid intake monitoring and may undergo colonoscopy or imaging to remove any polyps. The entire participation timeline extends beyond treatment to ensure thorough safety and immune response evaluation.
Actively Recruiting
Researchers are studying finerenone to find a better long-term treatment for children and young adults with heart failure and left ventricular systolic dysfunction LVSD, a condition where the hearts left side is weak and cannot pump blood well. The study aims to understand how safe finerenone is and how well it works when added to standard heart failure treatments in participants from newborns up to 18 years old. Participants will receive finerenone treatment for up to 9 months while continuing their usual heart failure care. The study includes children and young adults who joined an earlier finerenone trial and newly enrolled newborns under 6 months old with LVSD. Participants will attend at least six visits during the treatment period, where various health checks and tests will be done. During the study visits, researchers will measure vital signs, take blood samples, perform heart tests like electrocardiograms and echocardiograms, and ask about medication use and any medical problems. Parents or guardians of newborns and infants will provide feedback on how acceptable the study drug formulation is. After finishing treatment, participants will have a follow-up health check about one month later. The study will monitor safety by tracking medical problems and changes in potassium levels, blood pressure, and kidney function.
Actively Recruiting
Researchers are studying children with heart failure caused by left ventricular systolic dysfunction LVSD, a condition where the heart cannot pump enough blood. The goal is to see if the drug finerenone, which blocks a protein related to inflammation and scarring, can help the heart pump better compared to a placebo. This is the first study to test finerenone specifically in children with heart failure and LVSD, focusing on safety and effects on heart stress markers. Participants aged 6 months to under 18 years will be randomly assigned to receive either finerenone or a placebo for about three months, alongside their regular heart failure treatments. After this period, those who qualify may join an additional nine-month open-label phase where all receive finerenone. Those who do not join the extension will have a follow-up visit one month after finishing treatment. During the study, participants will visit the clinic at least three times for physical exams, heart tests including ECG and echocardiogram, blood tests, and measurements like blood pressure and heart rate. Researchers will track changes in a heart stress protein called NT-proBNP, monitor safety by recording any adverse events, and measure other heart function markers. The total study duration can be up to about a year including the extension and follow-up.
Actively Recruiting
Researchers are studying zongertinib, a medicine given as tablets once or twice daily, in adults with advanced cancers that have changes in the HER2 gene, including non-small cell lung cancer with specific HER2 mutations. The study has two parts the first aims to find the highest safe dose of zongertinib, and the second tests whether this dose can shrink tumors. This is a phase 1, open-label trial with participants who have not responded to previous treatments. In the first part, patients receive increasing doses of zongertinib alone to determine the maximum tolerated dose. Once this dose is established, it is used in the second part to evaluate tumor response. Participants continue taking zongertinib as long as they tolerate it and benefit. The study includes several cohorts, some based in the USA, Japan, and China. During the study, doctors regularly check patients health, monitor tumors using criteria like RECIST 1.1 and RANO-BM for brain metastases, and record any side effects possibly caused by zongertinib. The study measures outcomes such as maximum tolerated dose, dose-limiting toxicities, tumor response, disease control, progression-free survival, quality of life, and overall survival over up to 12 months. Participants remain in the trial as long as treatment is beneficial and tolerable.
Actively Recruiting
Researchers are studying colorectal cancer patients undergoing surgery to see if using two drugs together around the time of surgery can reduce cancer spread and improve survival. The study focuses on how stress-related chemicals released during the perioperative period may promote cancer progression and tests whether blocking these chemicals with propranolol and etodolac can have anti-metastatic effects. The trial is a Phase II, double-blind, placebo-controlled study involving 200 patients. Participants will take propranolol and etodolac orally for 20 days, starting five days before surgery. The propranolol dose changes over time, starting lower before surgery, increasing on surgery day, and tapering afterward. Etodolac is given consistently twice daily during the entire period. There is also a placebo group following the same schedule. The study compares the effects of the drug combination versus placebo in preventing cancer recurrence. During the trial, patients will be monitored for survival outcomes over five years, including disease-free survival and overall survival. Biological markers in tumor tissue and blood will be assessed about one year after surgery to understand anti- and pro-metastatic processes. Safety will be tracked through adverse events within 30 days post-surgery, and psychological health, including depression and fatigue, will also be evaluated before and after surgery. The total follow-up time extends to five years.
Actively Recruiting
Researchers are evaluating if combining ONC201 with various drugs is effective for treating children and young adults aged 2 to 39 years with diffuse midline gliomas DMGs, including diffuse intrinsic pontine gliomas DIPGs. The study uses an adaptive platform design with multiple cohorts based on disease stage newly diagnosed, post-radiation without progression, and progression stages. Novel agents may be added based on emerging preclinical data, and some cohorts include repeated intratumor infusions of DNX-2401. This is a phase II, open-label, multi-arm trial sponsored by the University of California, San Francisco. Treatment varies by cohort and includes oral ONC201 and paxalisib, radiation or re-irradiation therapy, and intratumoral DNX-2401 infusions given through a specialized cannula. Some participants may receive ONC201 as a safety lead-in before standard biopsy or radiation. Cycles repeat every 28 days in maintenance phases when no unacceptable side effects occur. Cohorts differ by timing related to radiation therapy and molecular tumor characteristics, with some participants receiving combination targeted therapies based on tumor or cerebrospinal fluid molecular profiles. Participants undergo assessments including tumor tissue collection, imaging, and laboratory tests. They are monitored for progression-free survival, overall survival, safety, and drug dosing effects. Follow-up visits occur at 30 days post-treatment and then every 3 months for up to 5 years or until withdrawal or death. Researchers also evaluate biomarkers, pharmacokinetics, immune cell changes, and quality of life measures. The study duration extends until June 2029, with primary completion expected by the end of 2027.
1-10 of 35
1